Trials / Completed
CompletedNCT00769041
A Thorough EKG Safety Study of TA-1790 (Avanafil)
A Blinded, Randomized Crossover Trial to Define the ECG Effects of TA-1790 (Avanafil) Using a Single Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin in Healthy Men: A Thorough ECG Trial
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- VIVUS LLC · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic (800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | moxifloxacin | 400mg |
| DRUG | avanafil | 100mg single dose |
| DRUG | avanafil | 800mg single dose |
| DRUG | sugar pill | single dose |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-10-08
- Last updated
- 2011-01-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00769041. Inclusion in this directory is not an endorsement.